Temporal trends in characteristics and outcomes of patients undergoing percutaneous mitral valve repair

Table 3 Procedural and clinical outcomes, mean ±SD, n (%)

Variable	Pooled real-life variables	EVEREST program, population size	EVEREST vs pooled variable, MD or OR (95%CI)	COAPT trial, population size	COAPT vs pooled variable, MD or OR (95%CI)	MITRA-FR trial, population size	MITRA-FR vs pooled variable, MD or OR (95%CI)
First five-year period
Post procedure
One device implanted	50.6 (41.2-60.0); I2 = 92	-	-	106/293 (36.2)	0.78 (0.61-1.00)	63/138 (45.7)	0.83 (0.59-1.18)
Two devices implanted	42.4 (35.2-49.8); I2 = 88	-	-	157/293 (53.6)	1.56 (1.22-1.99)	62/138 (44.9)	1.10 (0.78-1.56)
Three or more devices implanted	4.2 (2.9-5.7); I2 = 14	-	-	24/293 (8.2)	1.96 (1.19-3.21)	13/138 (9.4)	2.28 (1.21-4.29)
MR grade 1+	56.1 (48.5-63.5); I2 = 90	307/589 (52.1)	0.82 (0.69-0.98)	214/260 (82.3)	3.51 (2.53-4.86)	54/123 (43.9)	0.59 (0.41-0.85)
MR grade 2+	39.5 (33.0-46.2); I2 = 87	215/589 (36.5)	1.02 (0.84-1.22)	33/260 (12.7)	0.26 (0.18-0.37)	23/123 (18.7)	0.41 (0.26-0.64)
MR grade ≤ 2+	93.2 (89.6-96.2); I2 = 90	523/589 (88.8)	0.58 (0.44-0.78)	247/260 (95.0)	1.40 (0.79-2.48)	115/123 (93.5)	1.06 (0.71-2.19)
MR grade ≥ 3+	8.2 (5.4-11.6); I2 = 87	66/589 (11.2)	1.43 (1.07-1.91)	13/260 (5.0)	0.60 (0.34-1.06)	8/123 (6.25)	0.79 (0.38-1.64)
At follow-up
NYHA I/II at 12 months	74.4 (68.6-79.9); I2 = 77	511/616 (83.0)	1.74 (1.38-2.19)	171/237 (72.2)	0.931 (0.69-1.25)	76/112 (67.8)	0.76 (0.50-1.13)
MR grade ≤ 2+ at 12 months	85.1 (79.7-89.8); I2 = 88	349/413 (84.5)	1.20 (0.90-1.60)	199/210 (94.8)	3.98 (2.15-7.37)	79/97 (81.4)	0.97 (0.57-1.63)
All-cause mortality within 12 months	20 (15.7-24.6); I2 = 74	138/616 (22.4)	1.15 (0.92-1.44)	57/302 (19.1)	0.92 (0.68-1.26)	37/152 (24.3)	1.28 (0.87-1.89)
Second five-year period
Post procedure
One device implanted	46.6 (40.6-52.5); I2 = 86	-	-	106/293 (36.2)	0.74 (0.57-0.95)	63/138 (45.7)	1.09 (0.77-1.55)
Two devices implanted	46.9 (43.2-50.7); I2 = 64	-	-	157/293 (53.6)	1.22 (0.96-1.56)	62/138 (44.9)	0.86 (0.61-1.22)
Three or more devices implanted	6.3 (3.2-10.2); I2 = 81	-	-	24/293 (8.2)	1.04 (0.66-1.62)	13/138 (9.4)	1.21 (0.67-2.19)
MR grade 1+	57.7 (49.4-65.7); I2 = 82	307/589 (52.1)	0.65 (0.54-0.78)	214/260 (82.3)	2.76 (1.98-3.84)	54/123 (43.9)	0.46 (0.32-0.67)
MR grade 2+	24.9 (18.3-32.0); I2 = 79	215/589 (36.5)	1.40 (1.15-1.70)	33/260 (12.7)	0.35 (0.24-0.52)	23/123 (18.7)	0.56 (0.35-0.89)
MR grade ≤ 2+	89.7 (82.6-95.3); I2 = 90	523/589 (88.8)	0.60 (0.44-0.81)	247/260 (95.0)	1.43 (0.80-2.56)	115/123 (93.5)	1.08 (0.52-2.26)
MR grade ≥ 3+	11.4 (2.9-23.6); I2 = 90	66/589 (11.2)	1.38 (0.97-1.96)	13/260 (5.0)	0.57 (0.31-1.05)	8/123 (6.25)	0.76 (0.36-1.62)
At follow-up
NYHA I/II at 12 months	75.1 (56.6-90.0); I2 = 93	511/616 (83.0)	1.54 (1.16-2.03)	171/237 (72.2)	0.82 (0.58-1.15)	76/112 (67.8)	0.76 (0.43-1.03)
MR grade ≤ 2+ at 12 months	87.4 (81.1-92.6); I2 = 83	349/413 (84.5)	0.73 (0.52-1.02)	199/210 (94.8)	2.41 (1.27-4.58)	79/97 (81.4)	0.58 (0.34-1.02)
All-cause mortality within 12 months	18.1 (11.5-25.8); I2 = 86	138/616 (22.4)	1.14 (0.90-1.46)	57/302 (19.1)	0.92 (0.67-1.28)	37/152 (24.3)	1.28 (0.85-1.91)

EVEREST: Endovascular Valve Edge-to-Edge Repair Study; COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation; MITRA-FR: Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation; 95%CI: 95% confidence interval; MD: Mean difference; OR: Odds ratio; LVEF: Left ventricular ejection fraction; LVEDV: Left ventricular end-diastolic volume; MR: Mitral regurgitation; NYHA: New York Heart Association; NYHA: New York Heart Association.